| 2.06 -0.05 (-2.37%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.94  |
1-year : | 3.29 |
| Resists | First : | 2.51 |
Second : | 2.82 |
| Pivot price | 2.4 |
|||
| Supports | First : | 2.02 |
Second : | 1.68 |
| MAs | MA(5) : | 2.15 |
MA(20) : | 2.44 |
| MA(100) : | 2.75 |
MA(250) : | 2.57 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 8.9 |
D(3) : | 9 |
| RSI | RSI(14): 33.6 |
|||
| 52-week | High : | 4.29 | Low : | 1.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ATHA ] has closed above bottom band by 8.6%. Bollinger Bands are 14.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.2 - 2.22 | 2.22 - 2.23 |
| Low: | 1.99 - 2 | 2 - 2.02 |
| Close: | 2.04 - 2.06 | 2.06 - 2.08 |
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Tue, 16 Apr 2024
Athira Pharma's US$14m Market Cap Fall Books Insider Losses - Simply Wall St
Mon, 15 Apr 2024
Athira Pharma Appoints Javier San Martin, M.D., as Chief - GlobeNewswire
Fri, 12 Apr 2024
Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Movies Canada
Thu, 11 Apr 2024
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of ... - GlobeNewswire
Wed, 03 Apr 2024
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual ... - Yahoo Finance
Tue, 12 Mar 2024
Will Athira Pharma Inc (ATHA) Stay at the Top of the Healthcare Sector? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 62.8 (%) |
| Shares Short | 1,010 (K) |
| Shares Short P.Month | 784 (K) |
| EPS | -3.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.41 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38 % |
| Return on Equity (ttm) | -64.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -101 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -0.67 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|